Telix Pharmaceuticals (TLPPF) Payables (2023 - 2026)

Telix Pharmaceuticals (TLPPF) has reported Payables for 4 consecutive years, with $180.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Payables changed N/A year-over-year to $180.5 million in Q2 2026; TTM through Jun 2026 was $180.5 million, a N/A change from a year earlier, with the FY2025 full-year figure at $163.5 million, up 57.29% from the prior year.
• Payables was $180.5 million for Q2 2026 at Telix Pharmaceuticals, up from $163.5 million in the prior quarter.
• Over five years, Payables peaked at $180.5 million in Q2 2026 and troughed at $53.8 million in Q4 2023.
• A 4-year average of $125.4 million and a median of $133.7 million in 2024 frame the typical range for Payables.
• Across the five-year window, Payables jumped 93.11% in 2024 and surged 57.29% in 2025, its largest moves.
• Over 4 years, Payables stood at $53.8 million in 2023, then jumped by 93.11% to $103.9 million in 2024, then surged by 57.29% to $163.5 million in 2025, then rose by 10.41% to $180.5 million in 2026.
• The last three Payables figures came in at $180.5 million (Q2 2026), $163.5 million (Q4 2025), and $103.9 million (Q4 2024), per Business Quant data.